Budesonide-Inteli Neb suspension for nebulization 0.25mg/ml, 2ml x 20 containers — Made in Italy — Free Delivery

Brand: Inteli Generics
Product Code: Budesonide-Inteli Neb
Availability: In Stock

$33.43

Description

Product description

Suspension for nebulization "Budesonide-Intel Neb" contains a powerful non-halogenated corticosteroid - budesonide, intended for the treatment of bronchial asthma in patients for whom the use of inhalers with spraying of medicinal substances with compressed air or in the form of a dry powder dosage form is ineffective or impractical. "Budesonide-Inteli Neb" is also recommended for use in infants and children with croup (a complication of an acute viral infection of the upper respiratory tract, also known as laryngotracheobronchitis or subglottic laryngitis), which is an indication for hospitalization.

Compound

The active ingredient is budesonide (0.25 mg / ml). One single-use container contains 0.5 mg budesonide.

Excipients: sodium chloride, sodium citrate, disodium edetate, polysorbate 80, anhydrous citric acid, water for injection.

Contraindications

Hypersensitivity to budesonide or to any other ingredient in the preparation.

Mode of application

The dosage of the preparation "Budesonide-Inteli Neb" must be adjusted depending on the individual needs of the patient.

The dose that is administered to the patient depends on the nebulization equipment used. Nebulization time and dose delivered are dependent on flow rate, nebulizer chamber volume and fill volume. The air flow rate through the device used for spraying should be 6-8 liters per minute. The appropriate fill volume for most nebulizers is 2-4 ml. The dose should be reduced to the minimum necessary to maintain proper control of bronchial asthma. The highest dose (2 mg per day) for children under 12 years old should be prescribed only in case of severe asthma and for a limited period of time.

Bronchial asthma (initiation of therapy)

At the beginning of treatment, during periods of exacerbation of bronchial asthma and with a decrease or termination of pre-oral administration of glucocorticosteroids, the recommended dose is:

adults (including elderly patients): usually 1-2 mg twice a day (in severe cases, the dose can be further increased);

children over 12 years of age: the dosage is the same as for adults;

children aged 6 months to 12 years old - 0.5-1 mg twice a day.

Bronchial asthma (supportive therapy)

The maintenance dose should be selected individually and should be equal to the lowest dose at which the patient is asymptomatic.

Adults (including elderly patients) and children over 12 years old: 0.5-1 mg twice a day.

Children aged 6 months to 12 years: 0.25-0.5 mg twice a day.

Patients taking oral glucocorticosteroids as maintenance therapy

"Budesonide-Inteli Neb" makes it possible to cancel or significantly reduce the dose of glucocorticosteroids for oral administration while maintaining control of bronchial asthma. To begin switching from oral steroids, the patient must be relatively stable. For about 10 days, use a high dose of beddesonide in a nebula in combination with the previously used steroid dose. Thereafter, the dose of oral steroids should be gradually reduced to the lowest possible level, such as 2.5 mg of prednisolone or equivalent per month. Often the use of an oral steroid can be completely discontinued by replacing it with Budesonide-Inteli Neb.

Dosing features

The preparation can be mixed with 0.9% saline and with spray solutions containing terbutaline, salbutamol, fenoterol, acetylcysteine, sodium cromoglicate or ipratropium bromide. The mixture should be used within 30 minutes.

Dosage recommendations:

0.25 - 1 ml;

0.5 - 2 ml;

0.75 - 3 ml;

1.0 - 4 ml;

1.5 - 6 ml;

2.0 - 8 ml.

For patients for whom it is desirable to increase the therapeutic effect, especially patients without a large amount of mucus in the airways, it is recommended to increase the dose of budesonide instead of combined treatment with oral corticosteroids, which is associated with a lower risk of systemic side effects.

Croup

For children with croup, the usual dose is 2 mg of nebulized budesonide. This dose should be used in one dose or twice in 1 mg with an interval of 30 minutes. The administration of the preparation can be repeated every 12 hours, for a total of up to a maximum of 36 hours, or until clinical improvement.

Way to use

Use Budesonide-Inteli Neb only with suitable nebulizers.

The container must be disconnected from the strip, gently shaken and opened by breaking off the tip of the tip. Carefully squeeze the contents of the container into the nebulizer chamber. Discard the empty container and cover the nebulizer chamber with a lid.

Budesonide-Inteli Neb should be administered using a jet nebulizer with a nozzle or an appropriate breathing mask. The nebulizer should be connected to an air compressor to ensure sufficient air flow (6-8 L / minute) and the filling volume should be 2-4 ml.

Application features

Pregnant

The results of a large prospective epidemiological study and the experience of international use of the preparation in the post-registration period indicate that treatment with inhaled budesonide during pregnancy did not lead to undesirable effects on the health of the fetus / newborn. Administration of budesonide during pregnancy requires careful weighing of the benefits to the woman versus the risks to the fetus.

Budesonide passes into breast milk. However, when using therapeutic doses of budesonide, no effect on a breastfeeding baby is expected. "Budesonide-Inteli Neb" can be used during breastfeeding.

Children

The preparation should be used in children according to indications.

Drivers

Budesonide does not affect or has little effect on the ability to drive vehicles and work with other mechanisms.

Overdose

The preparation "Budesonide-Inteli Neb" contains 0.1 mg / ml disodium edetate, which has been proven to cause bronchoconstriction if its level exceeds 1.2 mg / ml. Acute overdose of budesonide, even with excessive doses, is unlikely to present a clinically significant problem.

Side effects

Infections and invasions: often (from ≥ 1/100 to <1/10) - oropharyngeal candidiasis.

On the part of the digestive system: often (from ≥ 1/100 to <1/10) - nausea, mental disorders.

Respiratory, thoracic and mediastinal disorders: often (from ≥ 1/100 to <1/10) - cough, hoarseness, throat irritation.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, protected from light and out of reach of children. Store containers in an envelope to protect from light.

Shelf life is 3 years.

After opening the envelope, the containers it contains should be used within 3 months. After the end of this period, the remnants of the preparation must be disposed of. The contents of an open container must be applied within 12 hours. After the end of this period, the remnants of the preparation must be disposed of.

0 reviews

There are no reviews for this product.